CMN Markets May 2021 (open access edition)
Jun. 3, 2021
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
NKarta Therapeutics
Main focus: Natural killer cells for cancer treatment
Company stage: Clinical
Diseases: Solid and haematological cancers
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:NKTX)
Location: South San Francisco, CA, USA
Website: https://www.nkartatx.com/
Pipeline: https://www.nkartatx.com/pipeline/
Partners: CRISPR Therapeutics
Nkarta Therapeutics focuses on the development of natural killer (NK)-based cellular therapies. The company has developed a proprietary manufacturing platform that enables enhanced persistence, expansion and activity of NK and CAR-NK products. The company entered into a technology license agreement with CRISPR Therapeutics, that allows Nkarta to genetically modify its CAR-NK cell products. Furthermore, Nkarta and CRISPR Therapeutics are co-developing two programmes, one CAR-NK programme targeting CD70 and one combined NK + T cell programme.
